Webinar Video | Life Sciences Session #1: What’s new in the parallel world of parallel trade?

Webinar Video | Life Sciences Session #1: What’s new in the parallel world of parallel trade?
November 24, 2020

In our first Life Sciences Session, our experts Philippe de Jong and Kirian Claeyé talk you through a number of recent decisions and developments in the field of parallel trade of pharmaceuticals, medical devices and plant protection products, including:

  • The rebranding of generics to original brand reference products
  • The impact of the falsified medicines framework on parallel trade
  • Further points of attention when verifying in light of the BMS conditions

Contact

  • Philippe de Jong

    Partner

  • Kirian Claeyé

    Partner

Recommended articles

May 03, 2024

EU Court of Justice interprets import ban on Chinese animal products: fish oil for feed is not an exempted “fishery product”

On 21 March 2024, the EU Court of Justice (‘CJEU’) handed down its ruling in case C‑7/23, concerning a dispute between a feed company and the Federal Agency for the Safety of the Food Chain. The parties differed in their interpretation of an EU import ban on products of animal origin coming from China. The Council of State sought the CJEU’s guidance.

Read on
April 26, 2024

CJEU balances strict obligations for wholesalers of medicines with proportional penalties

On 21 September 2023, the EU Court of Justice ('CJEU’) handed down its ruling in the Apotheke B. case (C-47/22), and it is a good example of the high threshold set by the EU Court of Justice to uphold the Community Code’s main aim of protecting public health.

Read on
April 04, 2024

Hospital mergers no longer subject to the Belgian Competition Authority’s prior review

The legislator has now had the last word, by providing that, in principle, hospital mergers are no longer subject to the BCA’s prior review and approval.

Read on